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An increase in the incidence of empyema worldwide 
could be related to invasive pneumococcal disease 
caused by emergent nonvaccine replacement serotypes. 
To  determine bacterial pathogens and pneumococcal 
serotypes that cause empyema in children in Australia, we 
conducted a 2-year study of 174 children with empyema. 
Blood and pleural ﬂ  uid samples were cultured, and pleural 
ﬂ  uid was tested by PCR. Thirty-two (21.0%) of 152 blood 
and 53 (33.1%) of 160 pleural ﬂ  uid cultures were positive for 
bacteria; Streptococcus pneumoniae was the most common 
organism identiﬁ   ed. PCR identiﬁ  ed  S. pneumoniae in 74 
(51.7%) and other bacteria in 19 (13.1%) of 145 pleural 
ﬂ  uid specimens. Of 53 samples in which S. pneumoniae 
serotypes were identiﬁ   ed, 2 (3.8%) had vaccine-related 
serotypes and 51 (96.2%) had nonvaccine serotypes; 19A 
(n = 20; 36.4%), 3 (n = 18; 32.7%), and 1 (n = 8; 14.5%) 
were the most common. High proportions of nonvaccine 
serotypes suggest the need to broaden vaccine coverage. 
E
mpyema in children is a relatively uncommon disease 
that occurs in 0.7% of children with pneumonia (1). 
Many organisms cause empyema in children; Streptococcus 
pneumoniae is the most common (2–6). Other important 
causes, which are becoming increasingly frequent in 
several countries, are methicillin-sensitive Staphylococcus 
aureus (MSSA) (2,7,8) and methicillin-resistant S. 
aureus (MRSA). The latter is particularly problematic in 
indigenous communities (9). Other commonly identiﬁ  ed 
organisms include S. pyogenes, Haemophilus inﬂ  uenzae, 
Mycoplasma pneumoniae,  Pseudomonas aeruginosa, 
and other Streptococcus spp. (10). The identiﬁ  cation of 
causative organisms is usually determined by standard 
blood or pleural ﬂ  uid cultures. Cultures are limited in that 
the yield can be as low as 8% (11), possibly because of 
prior antimicrobial drug treatment. Molecular techniques, 
such as PCR, are more sensitive in detecting causative 
organisms than standard culture (11) but are not routinely 
employed in laboratories for clinical use.
The 7-valent pneumococcal conjugate vaccine (PCV7) 
(Prevenar; Wyeth, Philadelphia, PA, USA) was introduced 
in Australia for immunocompromised and indigenous 
children <2 years of age in 2001 and was added to the 
national immunization schedule for all children <2 years 
in 2005 (www.medicareaustralia.gov.au/public/services/
acir/index.jsp). Of >90 pneumococcal serotypes, the 7 
included in the vaccine were responsible for 50%–70% of 
invasive pneumococcal disease (IPD) in children in most 
populations at the time of its development (12).
Many reports from around the world suggest an 
increase in the incidence of empyema in children (1,6,13–
19). The reasons for this increase are unknown but may be 
related to IPD caused by emergent nonvaccine replacement 
serotypes, particularly serotypes 1, 3, and 19A after the 
introduction of PCV7 (14–20). However, this theory is 
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controversial because several studies identiﬁ  ed an increase 
in empyema prevalence before the introduction of PCV7 
(5,21,22). Because no Australian data exist on the bacterial 
causes of empyema, it is difﬁ  cult to determine whether 
incidence in Australia is similar to reported trends in North 
America (14,22), the United Kingdom (5,6,16,18,21), 
Spain (15,17), and France (13).
The aims of this study were to identify the bacterial 
causes of empyema in children by using molecular 
techniques and to assess the efﬁ  cacy of PCV7 by using 
molecular typing of invasive pneumococcal disease 
serotypes. This information may be helpful in deciding 
which of the newer conjugate pneumococcal vaccines 
should be introduced into national vaccination programs.
Methods
The Australian Research Network in Empyema was 
established in April 2007 and comprises all 13 major 
tertiary pediatric hospitals from all states and territories. 
Children with empyema were prospectively recruited over 
a 2-year period until April 2009.
Patients
A case of childhood empyema was deﬁ   ned by the 
principal site investigators as the presence of pus cells 
in the pleural ﬂ  uid or bacteria isolated from the pleural 
ﬂ  uid of a child with fever, respiratory symptoms, raised 
serologic inﬂ  ammatory markers, and pleural ﬂ  uid present 
on ultrasound image, chest radiograph, or computed 
tomography scan. Children with postoperative effusions 
were excluded.
Clinical data collected included age, sex, indigenous 
status, area of residence, risk factors, congenital or 
chromosomal abnormality, anatomic or functional 
asplenia, immunocompromise, and chronic illness. 
Vaccination status of recruited patients was obtained by 
either review of the child’s hand-held health records (Blue 
Book), contacting the Australian Childhood Immunisation 
Registry (with parental permission) for patients <7 years of 
age (www.medicareaustralia.gov.au/public/services/acir/
index.jsp), or, if these validated sources were unavailable, 
parental recall.
Microbiologic Investigations
Blood and pleural ﬂ   uid specimens were cultured 
at local hospital microbiology laboratories by standard 
culture method. If growth was detected, Gram staining 
was performed and liquid media were subcultured onto 
horse blood agar. Isolates were identiﬁ   ed by using 
conventional methods. Colonies resembling S. pneumoniae 
that contained gram-positive diplococci were identiﬁ  ed by 
optochin- susceptibility and bile-solubility testing.
A separate aliquot of pleural ﬂ   uid (in ideal cir-
cumstances, 10 mL) was collected, labeled according to 
the central coordinator’s de-identiﬁ  cation and specimen-
tracking database, and stored at −20°C. Pleural ﬂ  uid 
specimens were transported in batches on dry ice by a 
commercial transport company to the Centre for Infectious 
Disease and Microbiology Laboratory, Westmead Hospital, 
Westmead, New South Wales, Australia, for processing.
Streptococcus pneumoniae PCR
Total nucleic acid was extracted from pleural ﬂ  uid 
specimens by using either NucliSENS easyMAG Total 
Nucleic Acid Extractor (bioMérieux Australia Pty Ltd, 
Sydney, NSW, Australia) with enzymes and lysis buffer 
provided, or SIGMA GenElute Mammalian Genomic DNA 
Miniprep Kit (Sigma-Aldrich, Sydney, NSW, Australia) 
with lysis buffer provided plus proteinase K, following the 
manufacturer’s instructions.
S. pneumoniae PCR targeting the autolysin gene (lytA) 
was performed by using a TaqMan probe and primers as 
described by McAvin et al. (23), except that the result was 
read by spectroﬂ  uorometry and interpreted as described 
by Poddar et al. (24). Brieﬂ  y, a 25-μL PCR containing 
1.5 mmol/L MgCl2, 200 μmol/L dNTPs, 200 nmol/L of 
each primer, 120 nmol/L probe, 1.23U HotStarTaq DNA 
polymerase, and 10 μL of total nucleic acid yielded a 101-
bp product. The PCR cycling conditions included initial 
denaturation at 95°C for 15 min, followed by 45 cycles at 
96°C for 10 s, 63°C for 1 min, and a ﬁ  nal extension step 
of 72°C for 2 min. The endpoint results were analyzed 
by calculating the postread to preread ratio. Samples with 
ratios of >2.78 were reported as positive and conﬁ  rmed 
by using pulsed-ﬁ  eld gel electrophoresis on a 2% gel, 
at 200 V for 40 min. Samples with ratios of <1.21 were 
reported as negative. The limit of detection of the assay 
was 6 CFU/mL.
Pneumococcal Serotype Identiﬁ  cation
All samples in which S. pneumoniae was detected 
by PCR were examined by multiplex PCR reverse line 
blot (mPCR/reverse line blot [RLB]) to identify serotypes 
individually or in small groups of related serotypes 
(25,26). If serogroup 6 was identiﬁ  ed, serotype-speciﬁ  c 
PCRs targeting wciN (to distinguish serotypes 6A and 
6C) and the wciP single-nucleotide polymorphism, which 
distinguishes serotypes 6A and 6C from 6B (27), were 
performed. Samples that gave no signals in mPCR/RLB 
(result recorded as below detection level) and those in 
which only the S. pneumoniae positive control probes 
targeting  ply or lytA produced signals (nontypeable) 
were further tested when sufﬁ  cient DNA remained, by 
PCR and sequencing of the cpsA-B region of the capsular 
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polysaccharide synthesis (cps) gene cluster, as described 
and validated (28).
PCR for Other Pathogens
All pleural specimens were tested by separate 
in-house PCRs for the presence of H. inﬂ  uenzae,  M. 
pneumoniae, Chlamydia pneumoniae, and S. aureus DNA. 
M. pneumoniae and C. pneumoniae PCR used ﬂ  uorogenic 
probes with endpoint analysis in a ﬂ  uorometer. Primers 
and probes were as follows: C. pneumoniae (target PstI 
fragment): primers Lab2f, 5′-GG AGA TAA AAT GGC 
TGG ACG-3′; Lab 2r, 5′-TAT GGC ATA TCC GCT TCG 
G-3′; probe Lab2p, 5′-6-FAM CAC GGA AAT AAA 
GGT GTT GTT TCC AAA ATCG-6-TAMRA-3′ (29); M. 
pneumoniae (target P1 protein gene): primers MYP-Fw, 
5′-TCA GGT CAA TCT GGC GTG-3′; MYP-Rv, 5′-TCA 
AAC AGA TCG GCG ACT G-3′; probe MYP, 5′-(6-
FAM) AGT TAC CAA GCA CGA GTG ACG GAA A-3′ 
(BHQ-1).
Conventional agarose gel electrophoresis was used for 
H. inﬂ  uenzae PCR. Primers used were Hinf OmP 6F, 5′-
AAT GGT GCT GCT CAA ACT TT-3′; and Hinf Omp 6R, 
5′-TCT AAG ATT TGA ACG TAT TCA CC-3′.
Testing for S. aureus DNA was undertaken by using a 
commercial multiplex-tandem PCR targeting the S. aureus 
nuclease gene nuc, and methicillin-resistance gene mecA 
(MRSA Easy-plex assay kit; AusDiagnostics, Sydney, 
New South Wales, Australia), as recommended by the 
manufacturer.
Assessment of Data Accuracy
To assess the completeness of case ascertainment, 
we contacted the coding departments of all participating 
hospitals at the end of the study and asked them to 
provide data on the number of children 0–18 years of 
age with empyema (classiﬁ  ed according to International 
Classiﬁ  cation of Diseases [ICD] codes J86.0 [pyothorax 
with  ﬁ   stula] or J86.9 [pyothorax without ﬁ  stula])  who 
were discharged from each hospital from April 1, 2008, 
through April 30, 2009. This period was chosen because 
it represented a time when all hospitals were actively 
recruiting. These data were compared with our own.
Descriptive statistics were used for all analyses. 
No power calculation was required because this was 
an epidemiologic study aiming to capture all cases of 
empyema.
This study was approved by the local human research 
ethics committee at each site, and registered with The 
Australian and New Zealand Clinical Trial Registry 
(ACTRN12607000476437). Informed parental consent 
was obtained for each patient before blood and pleural ﬂ  uid 
samples were collected.
Results
A total of 174 children were recruited over a 2-year 
period from April 2007 through April 2009, with a median 
recruitment rate of 6 (range 0–19) per month. Over a 1-year 
period, study sites recruited a median of 51.5% (range 
0%–200%) of actual admissions identiﬁ  ed by ICD coding 
discharge summaries. Demographic information was 
available from 172 patients (Table 1); of these, 70 (40.7%) 
were fully vaccinated (median age 2.1 years, range 0.4–
5.3 years); 18 (10.5%) were partially vaccinated (median 
age 4.2 years, range 0.6–5.4 years); 56 (32.6%) were not 
vaccinated (median age 7.7 years, range 1–15.5 years); and 
28 (16.3%) had no record of vaccination status (median age 
6.1 years, range 0.6–14.4 years).
Of the 174 children recruited, culture results were 
available for 172; 140 had blood and pleural ﬂ  uid cultured, 
20 had only pleural ﬂ  uid cultured, and 12 had only blood 
cultured. Of 152 blood and 160 pleural ﬂ  uid cultures, 120 
(78.9%) and 107 (66.9%), respectively, were negative. The 
bacteria isolated are shown in Table 2.
PCRs for S. pneumoniae, H. inﬂ  uenzae, M. pneumoniae, 
C. pneumoniae, and S.  aureus were performed on 145 
(83.3%) pleural ﬂ  uid specimens (Figure 1). One or more 
of these organisms was detected by PCR in 88 specimens: 
S. pneumoniae, 74 (51.0%); S. aureus, 13 (9.0%; 1 
with S. pneumoniae); H. inﬂ  uenzae, 4 (2.8%; 3 with S. 
pneumoniae); M. pneumoniae, 1 (0.7%); C. pneumoniae, 1 
(0.7%; with S. pneumoniae). Of the 13 S. aureus–positive 
specimens, 6 were MSSA and 7 MRSA.
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Table 1. Characteristics of 172 children with empyema, Australia, 
2007–2009* 
Characteristic  Value
Median age, y (range) 3.9 (0.4–15.5) 
Sex
M 93 (54.1) 
F 79 (45.9) 
Indigenous status
Aboriginal 8 (4.7) 
Other 160 (93.0) 
Not recorded 4 (2.3) 
State/territory
Queensland 59 (34.3) 
New South Wales 52 (30.2) 
Victoria 37 (21.5) 
Western Australia 16 (9.3) 
South Australia 4 (2.3) 
Tasmania 2 (1.2) 
 Australian Capital Territory 2 (1.2) 
Northern Territory 0
Chronic respiratory diseases 7 (4.0) 
Congenital diseases 3 (1.7) 
Potentially immunocompromised 6 (5.5) 
Cardiac disease 1 (0.6) 
*Values are no. (%) unless otherwise indicated. RESEARCH
Pneumococcal serotypes were identiﬁ  ed in 52 (70.3%) 
of 74 S. pneumoniae PCR-positive specimens; 3 specimens 
contained 2 serotypes (Table 3). Sufﬁ  cient DNA could not 
be obtained for 22 S. pneumoniae–positive specimens to 
identify serotypes, including 14 in which there was no signal 
in mPCR/RLB and 8 in which 1 or both S. pneumoniae–
speciﬁ  c (ply and/or lytA) probe signals, but none of the 
serotype-speciﬁ  c probes, were positive on RLB.
Vaccination status was available for 45 (86.5%) of 52 
children who had a pneumococcal serotype detected on 
PCR. The effect of vaccination status on the acquisition of 
speciﬁ  c serotypes, in relation to age and vaccination status, 
was assessed (Figure 2).
Discussion
This study supports previous reports from different 
countries that have identiﬁ  ed S. pneumoniae, S. aureus, 
and S. pyogenes as notable causes of childhood empyema 
(2–4,8,17,21). Most (96.4%) of identiﬁ  ed pneumococcal 
serotypes were nonvaccine related, reﬂ  ecting  the 
effectiveness of the PCV7. Furthermore, this study 
highlights that PCR is more sensitive than culture for 
identifying pathogens.
Data on bacterial causes of childhood pneumonia in 
this geographic region are lacking (30). Before this study, 
the most comprehensive data relating to pneumococcal 
serotypes causing disease in children were from routine 
typing of sterile site isolates from cases of IPD reported 
to the Nationally Notiﬁ  able Diseases Surveillance System. 
However, surveillance of IPD does not speciﬁ  cally report 
on empyema.
By far, the most common organism identiﬁ  ed  was 
S. pneumoniae. A variety of organisms other than S. 
pneumoniae were detected by culture and PCR. After 
S. pneumoniae,  S. aureus was the next most common 
pathogen, which was identiﬁ  ed by culture in 17 pleural 
ﬂ  uid and 2 blood specimens (12 MSSA, 7 MRSA) and 
by PCR in 13 specimens (Table 2). The occurrence of 
MRSA as a cause of community-acquired pneumonia and 
empyema is of particular concern because it is associated 
with more severe disease and a higher rate of complications 
than MSSA (9).
H. inﬂ  uenzae was detected by PCR in 4 children, 3 of 
whom also had positive PCR results for S. pneumoniae. S. 
pyogenes, Mycobacterium tuberculosis, and P. aeruginosa 
were isolated only by culture (individual PCR assays for 
these organisms were not available), and M. pneumoniae 
was detected by PCR in 1 child (Figure 1). All of these 
organisms are recognized causes of empyema in children 
(10). Although C. pneumoniae is a recognized cause 
of lower respiratory tract infection in children (31,32), 
its contribution to empyema has not been investigated 
previously. It was detected by PCR in only 1 child, with S. 
pneumoniae in the same specimen, which suggests that C. 
pneumoniae is not a major cause of empyema in children.
This study conﬁ  rmed  the  ﬁ   ndings of others, 
demonstrating enhanced sensitivity of molecular 
techniques (11,33–35). PCR detected many more S. 
pneumoniae isolates in pleural ﬂ  uid than in cultures (51.0% 
vs. 7.5%), and thus routine use of PCR-based serotype 
identiﬁ  cation in children with empyema may improve the 
accuracy of pneumococcal disease surveillance, which is 
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Table 2. Bacteria isolated by culture of blood and pleural fluid 
samples and by PCR of pleural fluid samples from children with 
empyema, Australia, 2007–2009* 
Organism 
No. (%) positive samples 
Blood
culture,
n = 152 
Pleural fluid
Culture,
n = 160
PCR,
n = 145
Streptococcus pneumoniae 19 (12.5) 12 (7.5) 74 (51)
S. pyogenes 3 (2.0) 14 (8.8) NA
S. milleri NA 4 (2.5) NA
MSSA 1 (0.7) 11 (6.8) 6 (4.1)
MRSA 1 (0.7) 6 (3.8) 7 (4.8)
Coagulase-negative 
staphylococci
4 (2.6) 2 (1.3) NA
Haemophilus influenzae 1 (0.7) NA 4 (2.8)
Mycobacterium tuberculosis  NA 1 (0.6 NA
Pseudomonas aeruginosa  NA 1 (0.6) NA
Mycoplasma pneumoniae  NA  NA 1 (0.7)
Chlamydia pneumoniae  NA NA 1 (0.7)
Other† 4 (2.6) 4 (2.5) NA
*NA, not applicable; MSSA, methicillin-susceptible Staphylococcus aureus;
MRSA, methicillin-resistant S.s aureus.
†Blood cultures: 1 isolate each of Streptococcus sanguinis; 
Staphylococcus hominis (from a specimen in which S. aureus was also 
isolated); Neisseria meningitidis; and Actinomyces naeslundii. Pleural fluid: 
1 isolate each of Streptococcus oralis; Staphylococcus cohni; Eikenella 
corrodens; and Bacteroides fragilis (the last 2 from the same specimen, 
from which S. milleri was also isolated). Both MRSA and MSSA were 
cultured from 1 pleural fluid specimen. 
Figure 1. Flow diagram for PCR testing for bacterial pathogens 
in samples from children with empyema, Australia, 2007–2009. 
MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, 
methicillin-resistant S. aureus.Empyema in Children, Australia
essential for development of new vaccines with broader 
range of pneumococcal serotypes. In contrast, however, for 
4 patients who had a culture positive for S. aureus, PCR 
results were negative. We are unclear why this occurred, 
but this PCR was performed last in the sequence, and results 
may have been due to insufﬁ  cient DNA. Although PCR did 
not increase the yield of S. aureus, it can detect it more 
rapidly than culture, enabling rapid change to appropriate 
therapy, especially when MRSA is found.
Reports on childhood empyema pneumococcal 
serotype distribution from Europe and the United States 
show differences. Studies in Spain (8,17), the United 
Kingdom (16,21,36), and the United States (14) have 
reported a predominance of serotype 1, while in other US 
studies, 19A is the most common serotype (20,22); both are 
non–PCV7 serotypes. Bekri et al. (13) identiﬁ  ed serotypes 
1 and 19A as emerging serotypes in France and also showed 
that serotype 1 was predominant in children >5 years of age; 
serotype 19A appeared to only affect children <5 years of 
age. This age distribution was similarly reported in another 
study (37). The serotype distribution in our study was 
similar; serotypes 1, 3, and 19A were predominant (Figure 
2), and most serotypes 3 and 19A were identiﬁ  ed in children 
<5 years of age, similar to results previously reported (37). 
Although serotype 1 infections were identiﬁ  ed across all 
age groups, most were in children >5 years of age.
We were reassured that only 2 children in our study 
had serotypes covered by PCV7; 1 child was covered 
partially, and the other had not been vaccinated. Overall, 
this study suggests the efﬁ  cacy of the PCV7, as previously 
conﬁ  rmed (38). However, public health authorities should 
be concerned that most pneumococcal infections were 
caused by nonvaccine serotypes, possibly related to 
replacement disease after the introduction of PCV7 onto 
the national vaccination schedule in 2005. We do not 
have serotype data speciﬁ   c to empyema prior to 2005, 
but this has occurred in other countries and affects all 
IPD, including meningitis (39). Most studies that compare 
pre– and post–pneumococcal vaccine effects have shown 
near extinction of PCV7 serotypes, along with dramatic 
increases in nonvaccine serotypes, predominantly 1, 3, and 
19A (14,15,17,20).
Although the reasons behind serotype changes have 
not been determined fully, ongoing enhanced surveillance 
may help clarify them over time, enabling us to predict 
future serotype trends and tailor new vaccines accordingly. 
This ability is particularly relevant as 2 new vaccines with 
broader coverage of pneumococcal serotypes—10-valent 
pneumococcal conjugate vaccine, with additional serotypes 
1, 5, and 7F, and 13-valent pneumococcal conjugate 
vaccine, with additional serotypes 1, 3, 5, 6A, 19A, and 
7F—are being are being added to national vaccination 
schedules. The 10-valent vaccine offers protection against 
nontypeable  H. inﬂ  uenzae through the use of an H. 
inﬂ  uenzae conjugate protein.
Our study has several limitations, nevertheless. First, 
we cannot know whether the number of children recruited 
in this study is an accurate snapshot of Australia’s true 
empyema prevalence in children. However, after comparing 
ICD empyema codes with study recruitment rates over a 
1-year period, we determined that we recruited a median 
of 51.5% (range 0%–200%) of empyema patients admitted 
to all major pediatric tertiary hospitals recorded by ICD. 
A limitation of this approach is that we were not able to 
verify the coding accuracy in each of the 13 hospitals. One 
likely reason why we did not capture all the cases may be 
because some patients received treatment from physicians 
at participating centers who were unaware of the study. 
Also, some children may have received treatment at 
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Table 3. Streptococcus pneumoniae serotypes identified in 52 
PCR-positive specimens from children with empyema, Australia, 
2007–2009* 
Serotype No. (%) specimens
PCV7 serotypes 2
 14 1  (1.8)
 9V/9A 1 (1.8)
Nonvaccine serotypes 53
 19A 20  (36.4)
 3 18 (32.7)
 1 8 (14.5)
 7F/7A 2 (3.6)
 22F/22A 2 (3.6)
 6C 1(1.8)
 15F 1 (1.8)
 21 1 (1.8)
*Two serotypes were identified in 3 specimens: 19A/3, 19A/1, and 6C/15F. 
The multiplex PCR reverse line blot assay cannot distinguish some pairs 
or groups of closely related serotypes, including 7F/7A, 22F/22A, and 
serogroup 6. Individual serotypes within serogroup 6 were distinguished by 
using serotype-specific PCR. PCV-7, 7-valent pneumococcal conjugate 
vaccine. 
Figure 2. Streptococcus pneumoniae serotype distribution in 
relation to age and vaccination status of children with empyema, 
Australia, 2007–2009. PCV7, 7-valent pneumococcal conjugate 
vaccine.RESEARCH
smaller rural hospitals where the study was not conducted, 
even though we have recently shown that most patients 
are treated in 1 of the tertiary pediatric hospitals included 
in this study (1). We recruited patients from all states and 
territories in Australia, which is the strength of the study. A 
limitation of the PCR data is that the bacteria assessed were 
restricted to H. inﬂ  uenzae, M. pneumoniae, C. pneumoniae, 
and S. aureus. They are all potentially important bacterial 
pathogens in empyema in children, however (10). The use 
of broader PCR, such as 16sPCR, may have detected more 
organisms, but it is an expensive test and our previous 
experience suggests that the yield of notable pathogens is 
poor and that positive results often reﬂ  ect contamination.
In conclusion, we have demonstrated a wide variety of 
bacterial causes for empyema in children. Most infections 
were caused by non–PCV7 pneumococcal serotypes, 
which suggests that coverage of pneumococcal serotypes 
by vaccines needs to be broadened. Ongoing enhanced 
molecular surveillance is required, particularly to assess the 
effects of newer vaccines, such as 10-valent and 13-valent 
pneumococcal conjugate vaccines. 
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